Stockscreener 앱 받기
19.98
1.77%
-0.36
시간 외 거래:
19.80
-0.18
-0.90%
전일 마감가:
$20.34
열려 있는:
$20.295
하루 거래량:
2.47M
Relative Volume:
1.24
시가총액:
$2.26B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-9.8424
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
+11.25%
1개월 성능:
+0.05%
6개월 성능:
-28.83%
1년 성능:
-57.90%
1일 변동 폭
$19.81
$20.59
1주일 범위
$17.76
$20.75
52주 변동 폭
$16.98
$49.06
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
19.98 | 2.26B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Fierce Biotech Layoff Tracker 2025: Unity lays off entire workforce; Mammoth lets go of 24 staffers - Fierce Biotech
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - Louisiana First News
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - The Manila Times
Apellis Pharmaceuticals to Present Q1 2025 Results: Complement Medicine Leader's Financial Update - Stock Titan
Apellis (APLS) Receives Overweight Rating and Positive Outlook f - GuruFocus
(APLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Cantor Fitzgerald Initiates Coverage of Apellis Pharmaceuticals (APLS) with Overweight Recommendation - MSN
Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now? - Insider Monkey
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq
Apellis stock touches 52-week low at $17 amid market challenges - Investing.com Australia
Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Intermediate AMD Market Insights: Key Growth Drivers, Future - openpr.com
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
Craig Wheeler joins Apellis board, brings biopharma expertise By Investing.com - Investing.com South Africa
RBC Capital Lowers Price Target on Apellis (APLS) Amid Market Su - GuruFocus
Craig Wheeler to Join Apellis Board of Directors - citybiz
Apellis Pharmaceuticals appoints new board member - Investing.com Australia
Apellis Pharmaceuticals appoints new board member By Investing.com - Investing.com South Africa
Apellis Announces Craig Wheeler To Join The Board Of Directors - marketscreener.com
Craig Wheeler joins Apellis board, brings biopharma expertise - Investing.com Australia
Apellis Pharmaceuticals (APLS) Welcomes Craig Wheeler to Board of Directors | APLS Stock News - GuruFocus
Apellis Announces Craig Wheeler to Join the Board of Directors | APLS Stock News - GuruFocus
Apellis Announces Craig Wheeler to Join the Board of Directors - The Manila Times
RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating - marketscreener.com
Former Momenta CEO Who Led $13.4B Johnson & Johnson Deal Takes Strategic Role at Apellis - Stock Titan
Apellis Announces Craig Wheeler to Join the Board of Directors | - GuruFocus
Apellis Pharmaceuticals (APLS) Target Price Reduced by BofA Ahead of Earnings | APLS Stock News - GuruFocus
BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating - marketscreener.com
Geographic Atrophy Therapeutics Market Size in 7MM is expected - openPR.com
The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26% - simplywall.st
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis Pharma stock hits 52-week low at $21.66 amid market challenges - Investing.com Canada
Apellis Pharma stock hits 52-week low at $21.66 amid market challenges By Investing.com - Investing.com South Africa
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.71%
자본화:
|
볼륨(24시간):